Acquiring Company
Ambros Therapeutics
Acquired Company
Werewolf Therapeutics
IrvineBiotechnologyHealth CareTherapeuticsBiotechnologyHealth CareTherapeuticsDescription
Ambros Therapeutics is set to acquire Werewolf Therapeutics in a merger valued at approximately USD 47.5 million. The combined entity will be named Ambros Therapeutics and will seek a Nasdaq listing under the symbol AMBX. The merger requires approval from both stockholders and Nasdaq. Existing Werewolf stakeholders will receive contingent value rights tied to legacy assets.
Fundz sees it the moment Ambros Therapeutics makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Werewolf Therapeutics?
Werewolf Therapeutics was acquired by Ambros Therapeutics, based in Irvine. The deal was reported on October 2, 2026. Ambros Therapeutics is a biotech firm focused on developing a non-opioid pain medicine for Complex Regional Pain Syndrome type 1 (CRPS-1). Ambros Therapeutics is privately held and operates in Biotechnology.
When did Ambros Therapeutics acquire Werewolf Therapeutics?
Ambros Therapeutics's acquisition of Werewolf Therapeutics was reported on October 2, 2026. Ambros Therapeutics is set to acquire Werewolf Therapeutics in a merger valued at approximately USD 47.5 million. The combined entity will be named Ambros Therapeutics and will seek a Nasdaq listing under the symbol AMBX. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Werewolf Therapeutics do?
Werewolf Therapeutics is a biotechnology firm specializing in immuno-oncology. The company is transitioning its focus toward late-stage rare-disease programs. It conducts research and development to create new therapeutic solutions. It is privately held, operating in Biotechnology.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.